Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-3,380
Closed -$384K 60
2024
Q3
$384K Buy
+3,380
New +$402K 1.54% 21
2023
Q4
$213K Buy
+1,955
New +$203K 1.03% 25
2021
Q3
Sell
-2,580
Closed -$201K 59
2021
Q2
$201K Sell
2,580
-6,413
-71% -$477K 0.62% 42
2021
Q1
$662K Buy
+8,993
New +$663K 2.1% 12
2018
Q4
Sell
-24,357
Closed -$1.65M 76
2018
Q3
$1.65M Sell
24,357
-1,541
-6% -$98.2K 1.18% 23
2018
Q2
$1.5M Sell
25,898
-30,455
-54% -$1.72M 0.89% 35
2018
Q1
$2.93M Sell
56,353
-61,207
-52% -$3.31M 1.64% 18
2017
Q4
$6.31M Buy
117,560
+32,996
+39% +$1.83M 2.88% 8
2017
Q3
$5.17M Buy
84,564
+41,972
+99% +$2.54M 2.27% 14
2017
Q2
$2.6M Sell
42,592
-3,275
-7% -$199K 0.98% 35
2017
Q1
$2.78M Buy
45,867
+14,296
+45% +$867K 0.86% 42
2016
Q4
$1.77M Sell
31,571
-621
-2% -$36.3K 0.75% 41
2016
Q3
$1.92M Sell
32,192
-11,003
-25% -$643K 0.81% 42
2016
Q2
$2.37M Sell
43,195
-49,448
-53% -$2.63M 0.98% 34
2016
Q1
$4.68M Sell
92,643
-3,696
-4% -$181K 1.83% 15
2015
Q4
$4.86M Sell
96,339
-10,023
-9% -$505K 1.96% 17
2015
Q3
$5.01M Buy
106,362
+40,739
+62% +$2.16M 1.76% 19
2015
Q2
$3.56M Sell
65,623
-37,128
-36% -$2.08M 1.15% 35
2015
Q1
$5.64M Buy
+102,751
New +$5.82M 1.7% 20

Other funds holding MRK

PVG Asset Management's MRK Position: Q4 2024 in Review

PVG Asset Management sold out of Merck (MRK) in Q4 2024, closing a stake of 3,380 shares — an estimated $384K sold.

PVG Asset Management first reported a position in MRK in Q1 2015 and held it in 19 quarters. The position peaked at $6.31M in Q4 2017. 3,608 funds tracked by Wall St. Rank hold MRK as of Q4 2024.

  • PVG Asset Management reported no remaining Merck position as of Q4 2024 after selling out during the quarter.
  • PVG Asset Management sold 3,380 Merck shares in Q4 2024, an estimated $384K.
  • PVG Asset Management first reported a position in Merck in Q1 2015 and held it in 19 quarters.
  • PVG Asset Management's Merck position peaked at $6.31M in Q4 2017.
  • 3,608 funds tracked by Wall St. Rank held Merck as of Q4 2024.

Based on PVG Asset Management's 13F filing for Q4 2024, filed 21 Feb 2025.